Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Share-based Compensation (2021 - 2025)

Prime Medicine's Share-based Compensation history spans 5 years, with the latest figure at $4.5 million for Q4 2025.

  • For Q4 2025, Share-based Compensation fell 24.0% year-over-year to $4.5 million; the TTM value through Dec 2025 reached $29.3 million, up 12.28%, while the annual FY2025 figure was $29.3 million, 12.28% up from the prior year.
  • Share-based Compensation reached $4.5 million in Q4 2025 per PRME's latest filing, down from $12.7 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $12.7 million in Q3 2025 to a low of $1.1 million in Q4 2021.
  • Average Share-based Compensation over 5 years is $4.5 million, with a median of $4.4 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: soared 209.88% in 2024, then fell 24.0% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $1.1 million in 2021, then surged by 132.52% to $2.6 million in 2022, then surged by 72.07% to $4.4 million in 2023, then skyrocketed by 34.14% to $5.9 million in 2024, then fell by 24.0% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Share-based Compensation are $4.5 million (Q4 2025), $12.7 million (Q3 2025), and $6.3 million (Q2 2025).